<DOC>
	<DOCNO>NCT01893879</DOCNO>
	<brief_summary>This randomize clinical trial study investigational drug prevent lymphedema patient high risk undergo axillary lymph node dissection . The study drug may prevent lymphedema patient undergoing axillary lymph node dissection .</brief_summary>
	<brief_title>Placebo-Controlled Therapeutic Trial Prevention Lymphedema</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate efficacy study drug improve chronic lymphedema elucidate role inflammatory lymphangiogenic process pathogenesis disease . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive study drug orally ( PO ) thrice daily ( TID ) 1 year absence disease progression unacceptable toxicity . ARM II : Patients receive placebo PO TID 1 year absence disease progression unacceptable toxicity . After completion study treatment , patient follow 5 year .</detailed_description>
	<mesh_term>Lymphedema</mesh_term>
	<mesh_term>Ketoprofen</mesh_term>
	<criteria>Axillary lymph node dissection within precede 12 month Patients active cancer Patients lymphedema Infection bleeding tendency Patients medical contraindication nonsteroidal antiinflammatory drug ( NSAIDs ) , include history allergy , know gastrointestinal intolerance Other serious systemic illness ( e.g. , renal failure , hepatic dysfunction , congestive heart failure , neurological psychological impairment ) would impair patient ' ability participate Persons competent consent Patients aspirin therapy Minors ( &lt; 18 year age ) Pregnant and/or lactate woman Males</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>